on behalf of the Acute Leukemia Working Party of EBMT Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option for adult patients with T-cell ALL (T-ALL). Meanwhile, few allo-SCT data specific to adult T-ALL have been described thus far. Specifically, the optimal myeloablative conditioning regimen is unknown. In this retrospective study, 601 patients were included. Patients received allo-SCT in CR1, CR2, CR 42 or in advanced disease in 69%, 15%, 2% and 14% of cases, respectively. With an overall follow-up of 58 months, 523 patients received a TBI-based regimen, whereas 78 patients received a chemotherapy-based regimen including IV busulfan-cyclophosphamide (IV Bu-Cy) (n = 46). Unlike patients aged ⩾ 35 years, patients aged o 35 years who received a TBI-based regimen displayed an improved outcome compared with patients who received a chemotherapy-based regimen (5-year leukemia-free survival (LFS) of 50% for TBI versus 18% for chemo-only regimen or IV Bu-Cy regimens, P = 10 − 5 and 10 − 4 , respectively). In multivariate analysis, use of TBI was associated with an improved LFS (hazard ratio (HR) = 0.55 (0.34-0.86), P = 0.01) and overall survival (HR = 0.54 (0.34-0.87), P = 0.01) in patients aged o 35 years. In conclusion, younger adult patients with T-ALL entitled to receive a myeloablative allo-SCT may benefit from TBI-based regimens.
INTRODUCTION
T-cell ALL (T-ALL) is a T-cell precursor neoplasm that accounts for ∼ 25% of adult ALL. 1 T-ALL displays specific clinical and biological characteristics compared with B-ALL. T-ALL predominantly affects young male adults who usually exhibit a mediastinal enlargement and/or a pleural effusion. 1 The central nervous system (CNS) is involved in ∼ 10% of cases and WBC counts are usually higher in T-ALL than in B-ALL. 2 Prognostic factors specific to adult T-ALL have emerged in past years. [2] [3] [4] Younger age, male gender and WBC o 100 g/L are associated with a better overall survival (OS), whereas CNS involvement has no prognostic value. 2 Cytogenetics has little prognostic impact with the notable exception of complex karyotypes being associated with poorer outcome. 2 
Among various immunophenotypic T-ALL subtypes, thymic
T-ALL-characterized by the positivity of CD1a on leukemic cells-displays an improved outcome. 2 More recently, NOTCH1 or FBXW7 mutations have been shown to be associated with a better outcome. 4 At present, the pretransplant therapeutic strategies in T-and B-ALL are increasingly being distinguished, notably because of the development of lineage-specific drugs. [5] [6] [7] Adult T-ALL needs to be studied as a specific disease separately from B-ALL.
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a therapeutic option in adult T-ALL because of the beneficial immune-mediated GvL effect. 2 In the past 10 years, indications to proceed to allo-SCT have evolved in adult T-ALL because of the advent of minimal residual disease (MRD)-based monitoring. 8, 9 In adult ALL, patients with a post-induction MRD ⩾ 10 − 3 benefit from allo-SCT unlike patients with a post-induction MRD o 10 − 3
. 10 Few allo-SCT data specific to adult T-ALL have been described. 2, 7, 11 As T-ALL patients are usually young with a median age of ∼ 30 years, they often display few comorbidities and are eligible for myeloablative allo-SCT. 2 Whenever the indication to proceed to allo-SCT has been decided, physicians can choose among various conditioning regimens from TBI-based regimens such as TBI-cyclophosphamide (Cy) to chemotherapy-based regimens such as IV busulfan (Bu)-Cy. The optimal conditioning regimen remains unknown in this disease, especially in the IV Bu era. The aim of the present work was to evaluate the impact of conditioning regimens on clinical outcome in adult T-ALL patients who received an allo-SCT with a myeloablative regimen.
PATIENTS AND METHODS

Study design, data collection and selection criteria
The European Group for Blood and Marrow Transplantation (EBMT) registry is a voluntary working group of more than 500 transplant centers that are required to report all consecutive stem cell transplantations and subsequent follow-ups at a minimum of once a year (https://www.ebmt. org/Contents/Data-Management/Registrystructure/Pages/Registry-structure. aspx). Inclusion criteria were (1) all adult patients aged ⩾ 18 years (2) with T-ALL who received a first allo-SCT following (3) a myeloablative conditioning regimen (4) from a related or unrelated donor (5) irrespective of disease status. Regimens with single-dose TBI ⩾ 5 Gy, fractionated TBI ⩾ 8 Gy, oral Bu 48 mg/kg or IV Bu 46.4 mg/kg were considered myeloablative. 12 As autologous SCT often includes high-dose TBI, most patients who received prior autologous SCT were not eligible to TBI-based regimens and were a priori excluded from analysis. 13, 14 Patients who received cord blood or haploidentical allo-SCT were excluded from the present study. Investigators were requested to report on disease features, allo-SCT characteristics and patient outcome. Disease status-including CR, relapse or progressive disease-was based on cytologic response. Relapse, refractory or progressive disease were categorized as advanced disease. Informed consent was obtained from all patients. This study was performed in accordance with the Declaration of Helsinki and was approved by the Acute Leukemia Working Party (ALWP) of the EBMT. Primary end point for this study was to evaluate leukemia-free survival (LFS) and prognostic factors for LFS. Secondary end points were OS, nonrelapse mortality (NRM) and relapse incidence.
Statistical analysis
For OS, death from any cause was considered as an event. LFS was defined as survival with no evidence of relapse or progression. NRM was defined as death without evidence of relapse or progression. The probabilities of OS and LFS were estimated using the Kaplan-Meier estimator and curves were compared with the log-rank test. The probabilities of NRM, relapse incidence, acute and chronic GvHD were calculated using the cumulative incidence estimator to accommodate for competing risks. Cumulative incidence curves were compared using the Gray test. 15 For NRM, relapse was the competing risk, and for relapse, the competing risk was NRM. To study acute and chronic GvHD, we considered death to be a competing event. In all analyses, data on patients without an event were censored at last follow-up. All factors associated with a P-value of o 0.15 in the LFS or OS univariate analysis were included in a Cox proportional hazard regression model. Proportional hazard assumption was systematically Abbreviations: allo-SCT = allogeneic hematopoietic stem cell transplantation; ATG = anti-thymocyte globulin; CNS = central nervous system; CsA = cyclosporin A; MMF = mycophenolate mofetil; MTX = methotrexate; T-ALL = T-cell ALL.
Myeloablative allo-SCT in adult T-ALL X Cahu et al checked for all proposed models using the Grambsch-Therneau residualbased test (results provided in Supplementary Table 5) . 16 In order to test for a center effect, we introduced a random effect or frailty for each center into the model. 17 All tests were two sided. The type-1 error rate was fixed at 0.05 for determination of factors associated with time to event outcomes. Statistical analyses were performed with SPSS 19 (SPSS Inc./IBM, Armonk, NY, USA) and R 2.13.2 (R Development Core Team, Vienna, Austria) software packages.
RESULTS
Patients and allo-SCT characteristics A total of 601 patients was included in the present study. Patient characteristics are described in Table 1 . Briefly, median age was 30 (range, 18-63) years with a predominant male gender (73%). At diagnosis, the CNS was involved in 15% of cases and WBC were ⩾ 100 g/L in 29% of cases. T-ALL immunophenotype was thymic for 21% of patients.
Although decision to proceed to allo-SCT was at the physician's discretion, patients received allo-SCT in CR1, CR2, CR 42 or in advanced disease in 69, 15, 2 and 14% of cases, respectively. Allo-SCT characteristics and conditioning regimens are described in Tables 2 and 3 , respectively. In all, 523 patients (87%) received a high-dose TBI-based regimen, whereas 78 patients (13%) received chemotherapy-only regimens. Chemotherapy regimens were scattered in 40 different centers (46% of all centers), most of which (77%) administered both TBI-and chemotherapy-based regimens. The most frequent TBI-based regimen was TBI-Cy (n = 403, 67%), whereas the most frequent chemotherapy-only regimen was IV Bu/Cy (n = 46, 8%) (Supplementary Table 1 ). Although the choice of conditioning regimen was at the physician discretion, patients with chemotherapy-based regimens exhibited similar T-ALL diagnostic features compared with patients with TBIbased regimens (Table 1) . However, disease status at allo-SCT was different in TBI and chemo-only regimens, with more CR1 patients in the TBI group (Table 1) .
Impact of diagnostic T-ALL features on clinical outcome
With a median follow-up of 58 months (range, 2-146), the overall 5-year LFS and OS was 41% (95% confidence interval (CI), 37-46%) and 45% (95% CI, 40-49%), respectively. The overall 5-year NRM was 25% (95% CI, 22-29%) and the 5-year relapse incidence was 33% (95% CI, 29-37%). With an overall engraftment rate of 98%, the cumulative incidence of grade II-IV acute GvHD was 38% (95% CI, 34-43%) at day 100 and the cumulative incidence of limited or extensive chronic GvHD was 42% (95% CI, 38-46%) at 5 years.
In univariate analysis, T-ALL prognostic factors such as patient gender, WBC count or complex karyotype did not have any prognostic value following allo-SCT (Table 2 ). Of note, neither CNS involvement at diagnosis nor T-ALL immunophenotype significantly affected allo-SCT outcome ( Table 2) .
Impact of conditioning regimens and allo-SCT characteristics on patient outcome Not surprisingly, disease status at allo-SCT was a significant prognostic factor in both LFS and OS (Table 2 ). There was a trend for a better outcome for bone marrow-derived stem cells compared with PBSCs ( Table 2 ). The impact of TBI on clinical outcome was analyzed. Patients who received a TBI-based regimen had a 5-year LFS of 44% (95% CI, 40-48%) versus 25% (95% CI, 15-35%) for chemotherapy-only regimen (P = 4 × 10 − 4 ). Similarly, patients with a TBI-based conditioning regimen displayed an improved 5-year OS compared with patients with a chemotherapy-only regimen (47% versus 28%, P = 4 × 10
). In the TBI group, the cumulative incidence of grade II-IV acute GvHD at day 100 was 40% (95% CI, 35-45%) vs 27% (95% CI, 16-38%) for the chemotherapy group (P = 0.02). The 5-year cumulative Abbreviations: allo-SCT = allogeneic hematopoietic stem cell transplantation; ATG = anti-thymocyte globulin; CI = confidence interval; CNS = central nervous system; LFS = leukemia-free survival; OS = overall survival; T-ALL = T-cell ALL.
incidence of limited or extensive chronic GvHD was also increased in the TBI group (44%, 95% CI, 40-49%) compared with the chemotherapy group (30%, 95% CI, 21-40%; P = 0.02). Importantly, TBI-based regimens benefit only patients o 35 years old and not patients X35 years old (Figure 1 and  Supplementary Table 2 ). Patients o35 years of age who received a TBI regimen (n = 351) displayed an improved OS and LFS (53% and 50%, respectively) compared with patients with a chemo-only regimen (n = 54; 21% and 18%, respectively; P o 10 − 5 for both tests; Figure 1 and Supplementary Table 2 ). In patients o 35 years of age, the relapse incidence was 30% in the TBI group versus 60% in the chemo-only group (P o 10 − 5 ), whereas the NRM was similar in both groups (21% in the TBI group versus 22% in the chemo group, P = 0.75) (Supplementary Table 2 ). On the contrary, patients X35 years old did not benefit from the use of TBI (OS of 34% in the TBI group (n = 172) versus 45% in the chemo group (n = 24), P = 0.23; LFS of 32% in the TBI group versus 41% in the chemo group, P = 0.48; Figure 1 and Supplementary Table 2 ). Patients X35 years old who received a TBI-based regimen displayed a decreased relapse incidence (30% versus 50% for the chemo group, P = 0.04) but also a significantly increased NRM (38% versus 9% for the chemo group, P = 0.01, Supplementary Table 2 ).
Impact of TBI in patients o 35 years old
The impact of TBI was analyzed in the group of patients o 35 years old. Because disease status was unbalanced between the TBI and chemo-only group (Supplementary Table 3) , the impact of TBI was specifically studied in the CR1, CR2 and advanced disease categories (Table 3 and Figure 2 ). In CR1 and CR2 patients, OS and LFS were statistically improved in the TBI group compared with the chemo-only group (Figure 2 ). In CR 42 or advanced disease patients, OS was significantly increased in the TBI group. Noteworthy, none of the patients in advanced disease could benefit from a long-term survival following a chemo-only regimen (Figure 2) .
The impact of TBI on OS and LFS of patients o35 years old was evaluated in multivariate analysis. Use of TBI as part of the conditioning regimen remained significantly associated with an improved LFS (hazard ratio (HR) = 0.55 (0.34-0.86), P = 0.01) and OS (HR = 0.54 (0.34-0.87), P = 0.01) along with disease status (Table 4) . Of note, no center effect could be demonstrated (Table 4) . Prognostic factors for a decreased relapse incidence were use of TBI and disease status ( Table 4) .
Impact of specific conditioning regimens in T-ALL among younger patients To address the issue of heterogeneity in chemo-only conditionings (Supplementary Table 1) , chemotherapy regimens were categorized in IV Bu-Cy versus other chemo-only regimens in patients o 35 years of age (Table 5) . Patients who received a TBIbased regimen displayed an improved OS and LFS as well as a decreased relapse incidence compared with patients who received IV Bu-Cy (Table 5) . Clinical outcome was similar in the IV Bu-Cy and the 'other chemotherapy' group, thus showing that grouping these two groups was feasible in our analyses (Table 5) . Similarly, patients who received a TBI-based regimen exhibited an Abbreviations: LFS = leukemia-free survival; NRM = non-relapse mortality; OS = overall survival.
Myeloablative allo-SCT in adult T-ALL X Cahu et al improved OS and LFS along with a decreased relapse incidence compared with patients who received IV Bu (Supplementary Table 4 ).
DISCUSSION
Myeloablative allo-SCT can be achieved with various conditioning regimens. Whereas TBI was used early in the history of allo-SCT, oral Bu was introduced in the 1980s. 18, 19 Numerous conditioning regimens can be found in the allo-SCT armamentarium in TBIbased regimens from Cy replacement by VP16 to addition of a third molecule to the standard TBI-Cy. [20] [21] [22] The underlying disease is a key aspect in the choice of the conditioning regimen. [23] [24] [25] Recent studies have demonstrated that IV Bu-Cy should be preferred to TBI-Cy in myeloid malignancies. 24, 25 In pediatric or adult ALL, a better outcome has been described for TBI-based regimens compared with chemotherapy-based regimen such as oral Bu-Cy. 23, [26] [27] [28] Meanwhile, the improved results with TBI may result from the variable pharmacokinetics reported for oral Bu and/or the increased NRM reported for oral Bu-Cy. 23, 27 As IV Bu has progressively replaced oral Bu in the past decade, these unspecific ALL data may not apply in the IV Bu era or in the specific T-ALL disease. 29 In this context, the present study reports the allo-SCT experience of 89 EBMT centers on adult T-ALL over the 2000-2010 period. This large number of transplant centers combined with the rather large study period demonstrates the rarity of the situation that likely accounts for the lack of data so far. This retrospective study mirrors an unspecific ALL evidence-based attitude of physicians, with TBI-Cy being widely used among EBMT participating centers. In the present analysis, a better outcome after TBI-based regimen compared with chemotherapy-based regimen was demonstrated in younger patients. On the contrary, patients 435 years old did not take advantage of TBI.
Although disease status at allo-SCT differed between the TBI and the chemotherapy groups, the benefit for TBI in younger patients holds true in CR1, CR2 or advanced disease subgroups. The superiority of TBI-based regimens was also demonstrated in multivariate analysis for both LFS and OS irrespective of disease status. To take the heterogeneity of regimens into account, TBIbased regimens, IV Bu-Cy and other chemo-only regimens were compared. Patients o 35 years of age who received a TBI-based regimen displayed a better outcome than patients with an IV Bu-Cy regimen mainly because of a decreased relapse incidence. As the 'other chemo-only' group is heterogeneous, we do not exclude that another chemo-only regimen might be superior to TBI-based regimens.
The improved OS and LFS in the TBI group results from a reduced relapse incidence along with a similar NRM as demonstrated by uni-and multivariate analyses. In myeloablative regimens, the reduced relapse incidence may result from the conditioning-induced cytoreduction and/or from the GvL effect. On the one hand, irradiation induces a significant antitumoral activity against lymphoid malignancies. In this respect, none of the 15 patients who were transplanted in advanced disease with chemotherapy-based regimen could benefit from a long-term survival. On the other hand, chronic GvHD induces a significant GvL effect. 30 In this analysis, TBI regimens induced more acute and chronic GvHD than chemotherapy-only regimens.
The present study has a few limitations. Because of the retrospective nature of our study, we cannot exclude any difference between TBI and chemo-only groups such as pre-SCT therapy or molecular features (NOTCH1/FBXW7). 4 Furthermore, the choice of conditioning regimen was at the physician discretion. T-ALL occurs in young patients with no predisposing comorbidity and all patients were considered to be eligible to myeloablative regimens. However, we cannot exclude that some patients may have presented any specific contraindication to one of the aforementioned regimen. Of note, mediastinal radiation therapy is currently not recommended in T-ALL. 31 In cases of CNS involvement, CNS irradiation does not exclude patients from subsequent TBI. 32 The present study did not aim at identifying which T-ALL patients should undergo allo-SCT. Patients with CNS involvement or complex karyotypes were overrepresented compared with a standard T-ALL cohort, mirroring a probable selection procedure among T-ALL cases.
2 Although allo-SCT indications were based on cytologic response and/or diagnostic features in the early 2000's, MRD-based monitoring has drastically modified allo-SCT indications notably in CR1. 9 As a consequence, the present cohort likely includes adult T-ALL cases with heterogeneous allo-SCT indications. Although the present study reflects the allo-SCT experience during the 2000-2010 period among a large series of transplant centers, this analysis could not take MRD data into account and may not perfectly match current T-ALL indications for allo-SCT. 9, 10 Of note, T-ALL immunophenotype or CNS involvement at diagnosis did not affect allo-SCT outcome and should not preclude patients from allo-SCT. Abbreviations: BM = bone marrow; CI = confidence interval; HR = hazard ratio; LFS = leukemia-free survival; NRM = non-relapse mortality; OS = overall survival; RI = relapse incidence. Abbreviations: Bu-Cy = busulfan-cyclophosphamide; LFS = leukemia-free survival; NRM = non-relapse mortality; OS = overall survival.
Myeloablative allo-SCT in adult T-ALL X Cahu et al
In conclusion, although the choice of conditioning regimen has been solely based on ALL studies for decades, the present analysis provides physicians with a significant cohort of adult patients with T-ALL. Analysis of the transplant activity during the 2000-2010 period suggests that patients with T-ALL should receive TBI-based regimens rather than IV Bu-Cy. Further prospective studies are warranted to confirm these data in the MRD era and to compare other chemo-only regimens with TBI-based regimens.
